HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The use of a polymeric sealant for prevention of posttransplantation lymphocele.

Abstract
The aim of this study was to investigate the effectiveness of a synthetic polyethy lenglycol (PEG) sealant to prevent lymphocele formation after kidney transplantation. The examined group consisted of 719 recipients including 294 female and 425 male who were immunosuppressed with a calcineurin inhibitor, plus basiliximab since 1999, and with mycophenolate mofetil in addition since 2000. We retrospectively analyzed the incidence of lymphoceles among 545 recipients operated between November 1999 and November 2007 (group I), 93 recipients at standard risk for lymphocele transplanted between December 2007 and December 2009 (group II) in whom we performed only routine ligation of the lymphatic vessels during preparation of the graft, and 31 patients also transplanted between December 2007 and December 2009 who were at higher risk for lymphocele (group III) and underwent an off-label application of the PEG sealant. There was no significant difference in patient demographic features among the groups. In total, 21 group I, patients (3.5%) developed symptoms of a lymphocele that required ≥1 corrective procedures, whereas only 1 group II patient (1.07%) developed a lymphocele and no group III patient evidenced a symptomatic lymphocele. No adverse events were observed among group III patients after PEG sealant application. although the preliminary results are interesting, a prospective randomized study is required to assess the cost-effectiveness of PEG sealant to prevent lymphocele formation.
AuthorsL Berardinelli, M Raiteri, A Pasciucco, M Carini
JournalTransplantation proceedings (Transplant Proc) Vol. 43 Issue 4 Pg. 1072-3 (May 2011) ISSN: 1873-2623 [Electronic] United States
PMID21620056 (Publication Type: Journal Article)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Tissue Adhesives
  • Polyethylene Glycols
  • Basiliximab
  • Mycophenolic Acid
Topics
  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal (therapeutic use)
  • Basiliximab
  • Calcineurin Inhibitors
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Female
  • Graft Survival
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Infant
  • Italy
  • Kaplan-Meier Estimate
  • Kidney Transplantation (adverse effects, mortality)
  • Lymphocele (etiology, mortality, prevention & control)
  • Male
  • Middle Aged
  • Mycophenolic Acid (analogs & derivatives, therapeutic use)
  • Polyethylene Glycols (therapeutic use)
  • Recombinant Fusion Proteins (therapeutic use)
  • Retrospective Studies
  • Survival Rate
  • Time Factors
  • Tissue Adhesives (therapeutic use)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: